Emergent BioSolutions Inc. (EBS) Earnings History
Net Loss25 years of earnings data (2001–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Emergent BioSolutions Inc. (EBS) Earnings Overview
As of July 7, 2026, Emergent BioSolutions Inc. (EBS) reported trailing twelve-month net income of -$9M, reflecting +125.8% year-over-year growth. The company earned $-0.15 per diluted share over the past four quarters, with a net profit margin of 7.1%.
Looking at the long-term picture, EBS's 5-year EPS compound annual growth rate (CAGR) stands at -30.3%, signaling declining earnings. The company achieved its highest annual net income of $306M in fiscal 2020.
Emergent BioSolutions Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including SIGA ($20M net income, 24.6% margin), PRGO (-$1.82B net income, -33.5% margin), BRKR (-$12M net income, -0.3% margin), EBS has room to improve margins relative to the peer group. Compare EBS vs SIGA →
EBS Earnings vs Peers
Earnings metrics vs comparable public companies
EBS Historical Earnings Data (2001–2025)
23 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $53M | +127.6% | $110M | $0.93 | 7.1% | 14.8% |
| 2024 | -$191M | +74.9% | -$109M | $-3.60 | -18.3% | -10.4% |
| 2023 | -$761M | -259.4% | -$726M | $-14.85 | -72.5% | -69.2% |
| 2022 | -$212M | -196.4% | -$170M | $-4.22 | -18.9% | -15.2% |
| 2021 | $220M | -28.2% | $341M | $4.06 | 12.4% | 19.2% |
| 2020 | $306M | +461.1% | $439M | $5.67 | 19.4% | 27.8% |
| 2019 | $55M | -13.1% | $114M | $1.04 | 4.9% | 10.3% |
| 2018 | $63M | -24.1% | $90M | $1.22 | 8.0% | 11.5% |
| 2017 | $83M | +59.5% | $124M | $1.71 | 14.7% | 22.2% |
| 2016 | $52M | -17.6% | $106M | $1.13 | 10.6% | 21.6% |
| 2015 | $63M | +71.1% | $142M | $1.41 | 12.8% | 28.9% |
| 2014 | $37M | +18.0% | $89M | $0.88 | 9.1% | 22.1% |
| 2013 | $31M | +32.4% | $43M | $0.85 | 10.0% | 13.7% |
| 2012 | $24M | +2.2% | $37M | $0.65 | 8.3% | 13.0% |
| 2011 | $23M | -55.5% | $32M | $0.64 | 8.4% | 11.7% |
| 2010 | $52M | +66.0% | $74M | $1.59 | 18.1% | 25.7% |
| 2009 | $31M | +50.6% | $40M | $0.99 | 13.3% | 17.1% |
| 2008 | $21M | -9.8% | $30M | $0.68 | 11.6% | 16.8% |
| 2007 | $23M | +0.6% | $33M | $0.77 | 12.5% | 18.1% |
| 2006 | $23M | +44.4% | $38M | $0.93 | 14.9% | 24.9% |
| 2005 | $16M | +37.6% | $21M | $0.69 | 12.1% | 16.3% |
| 2004 | $11M | +2170.8% | $17M | $0.56 | 13.7% | 20.1% |
| 2001 | $-554,000 | - | $-364,000 | $-0.03 | -1.2% | -0.8% |
Download Data
Export EBS earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
25+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
EBS — Frequently Asked Questions
Quick answers to the most common questions about buying EBS stock.
What is EBS earnings per share (EPS)?
EBS trailing twelve-month (TTM) diluted EPS is $-0.15, reflecting +125.8% year-over-year growth. The 5-year EPS CAGR is -30.3%. Complete EPS history from 2001 to 2025 is available in the table on this page.
What is Emergent BioSolutions Inc.'s net income?
Emergent BioSolutions Inc. (EBS) trailing twelve-month net income is $-9M as of 2025. Earnings grew +125.8% year-over-year.
Is EBS profitable?
EBS is not currently profitable on a TTM basis, reporting a net loss of $-9M. Net margin is +7.1%. Investors should monitor for a return to profitability.
What is EBS's earnings growth rate?
EBS compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: -30.3%, 10-Year: -4.1%. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2001 to 2025.
What are EBS's profit margins?
Emergent BioSolutions Inc. net profit margin is +7.1%, operating margin is +14.8%, and gross margin is +47.2%. Margins are within a typical range for the sector. Return on Equity is +10.5%.
Is EBS growing earnings?
Yes, EBS earnings are accelerating — EPS growth of +125.8% exceeds the 5-year CAGR of -30.3%. TTM net income reached $-9M. Earnings momentum is strengthening.
What was EBS's best earnings year?
Emergent BioSolutions Inc.'s highest annual net income on record is $306M, achieved in fiscal year 2020. Earnings history on this page spans 2001 to 2025 and includes all annual and quarterly figures.
What were EBS's earnings last quarter?
EBS's most recent reported quarter was Q1 2026. Net income was $7M with diluted EPS of $0.07. For a full breakdown of all quarters, see the quarterly earnings table on this page.